Oncology news and insights from leading researchers and cancer centers.
Joined July 2012
- Tweets 46,200
- Following 3,563
- Followers 20,948
- Likes 5,384
6,444 Photos and videos
What happens to cancer patients' symptoms between clinic visits?
Dr Timothy Hembree shares how @MoffittNews is using AI-supported virtual care to extend symptom management beyond the clinic walls.
🔗 hubs.li/Q04kNGff0
1
1
5
189
🚨 Belzutifan pembrolizumab now FDA approved for adjuvant treatment of high-risk clear cell RCC following nephrectomy. First combo to beat an active immunotherapy comparator in this setting. 🔗 hubs.li/Q04lfxH10
1
1
2
185
🔬 #ASCO26 | Tucatinib trastuzumab/pertuzumab improved median PFS by ~9 months vs placebo in HER2 breast cancer across ALL key subgroups. @ErikaHamilton9 @SarahCannonDocs breaks down the #HER2CLIMB05 data. 🎥 targetedonc.com/view/dr-hami…
3
2
183
You asked. We got an answer. 💡
At #ASCO26, @KalinskyKevin @WinshipatEmory, answered one of our follower’s pressing questions on updates in lobular carcinoma #BreastCancer
2
1
244
New phase 2 data from #EHA2026: The FBEM conditioning regimen delivers 92.1% 2-year OS and 0% 100-day NRM in high-risk #ALL undergoing alloHSCT — with manageable GVHD across 203 patients. 🔬
#LeukemiaResearch #BoneMarrowTransplant #Hematology #Oncology
hubs.li/Q04lbTsR0
2
208
🚨 Breakthrough in #MultipleMyeloma treatment: KLN-1010, an in vivo anti-BCMA CAR T therapy, achieves 100% MRD negativity in relapsed/refractory patients, with some remaining progression free beyond 9 months. 🔬 #EHA2026
Read the full data 👉 targetedonc.com/view/kln-101…
2
189
🚨 FDA grants priority review to atezolizumab mFOLFOX6 for adjuvant dMMR/MSI-H stage III colon cancer.
ATOMIC trial: 50% reduction in recurrence/death vs. chemo alone. 3-yr DFS 86.3% vs 76.2%.
Already in NCCN guidelines. Full data 👇
hubs.li/Q04l5Y3v0
1
3
4
276
Day 1 at #EHA2026 is underway! 🩸 From oral sessions to hallway discussions, we’re highlighting key data as they emerge and expert perspectives from around the globe.
#EHA26 #Hematology #Oncology #BloodCancer #Leukemia #Lymphoma #myeloma
2
4
507
✅ Generic larotrectinib (Vitrakvi) moves closer to US patients with tentative FDA approval for the NTRK fusion–targeting TRK inhibitor. #oncology
hubs.li/Q04l2NQR0
3
4
263
🧬 FDA grants rare pediatric disease designation to opaganib for #neuroblastoma, adding to existing orphan drug status. What it means for the pipeline: hubs.li/Q04l1zLg0
1
2
171
Dr Ajaz Khan of @CityofHope breaks down the biggest advances from #ASCO26 in breast & lung cancer, including giredestrant, selpercatinib, ivonescimab, and the rising role of ctDNA and AI in oncology.
Watch the full recap 👇
hubs.li/Q04l1ql70
2
2
192
What do uveal melanoma, mucosal melanoma, and Merkel cell carcinoma have in common? They're rare, complex, and the focus of cutting-edge research.
Experts from @JeffersonUniv @PKU1898 @fredhutch break down their key presentations in this roundup 👇
targetedonc.com/view/asco-ro…
3
3
406
The phase 3 SENTRY trial showed selinexor plus ruxolitinib achieved SVR35 in 50% of patients vs 28% with ruxolitinib alone in frontline myelofibrosis, with a promising OS signal, though the total symptom score coprimary end point was not met.
hubs.li/Q04kM1600
1
3
314
Off-the-shelf CAR T therapy azer-cel earns FDA Fast Track for R/R CLL/SLL and MZL. What could allogeneic CAR T mean for your heavily pretreated patients?
hubs.li/Q04kKN9X0
1
1
164
Phase 3 KEYNOTE-D46/EVOKE-03 has been discontinued: sacituzumab govitecan pembrolizumab failed to reach statistical significance for PFS vs pembrolizumab monotherapy in first-line PD-L1–high mNSCLC.
🔗 hubs.li/Q04kS-v50
197
Updated data from #ASCO26 highlight advances in TNBC and HR breast cancer, including novel agents, biomarker strategies, and GLP-1 RA findings. There's more from Chicago than the late-breakers — here's what you might have missed. #BreastCancer #TNBC
hubs.li/Q04kNpFf0
138
What's shaping the future of breast cancer treatment? 🧬At #ASCO26, @PTarantinoMD @DFCI_BreastOnc breaks down:
→ KRAS inhibitor signals in breast cancer
→ ADC immunotherapy combinations gaining momentum
→ New breakthroughs in TNBC & HER2 disease
targetedonc.com/view/asco-20…
1
3
3
721
📽️WATCH: Dr Estelamari Rodriguez, @SylvesterCancer, talks tolododekin alfa a novel agent that achieves prolonged local IL-12 retention while minimizing systemic absorption in NSCLC #ASCO26 targetedonc.com/view/estelam…
3
292
📢 #ASCO26: Phase 3 data show giredestrant plus palbociclib misses significant PFS gain vs letrozole in ER /HER2– locally advanced or metastatic #BreastCancer, with similar safety, guiding future trials.
Read more: hubs.li/Q04ksgRy0
1
1
4
365
⭐ EXCLUSIVE: Get a sneak peek of what's to come at #EHA2026 this week in our new curated preview, including advances in #CLL, #myeloma, #MPNs, and more.
🩸 Find the preview here (free sign-up required): hubs.li/Q04ksnnz0
#EHA26 #Hematology #Oncology #BloodCancer
2
193